{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:48:06Z","timestamp":1760986086178,"version":"3.37.3"},"reference-count":28,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Despite the growing evidence of the clinical value of somatostatin receptor (SSTR) positron emission tomography (PET) in the evaluation of neuroendocrine tumors (NETs), its role remains to be clarified at different time points in the journey of patients with multiple endocrine neoplasia type 1 (MEN1). The rarity of the disease is however a significant impediment to prospective clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The goals of the study were to assess the indications and value of SSTR PET\/computed tomography (CT) in patients with MEN1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively included patients from 7 French expert centers for whom data on SSTR PET\/CT and morphological imaging performed at the same period were available. Detection rates of PET study were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and 8 patients were included. SSTR PET\/CT was performed at screening (n = 33), staging (n = 34), restaging (n = 37), and for peptide receptor targeted radiotherapy selection (n = 4). PET detected positive pancreatic lesions in 91% of cases at screening, with results comparable with magnetic resonance imaging but superior to CT (P = .049). Metastases (mostly lymph node [LN]) were present at the screening phase in 28% of cases, possibly due to the suboptimal value of screening morphological imaging in the assessment of nodal metastases and\/or a long delay between imaging studies. SSTR PET\/CT was considered superior or complementary to the reference standard in the assessment of LN or distant metastases in the vast majority of cases and regardless of the clinical scenario.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study shows the potential added value of SSTR PET in the assessment of MEN1-associated NETs and provides great impetus toward its implementation in the evaluation of patients with MEN1.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab891","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T05:51:11Z","timestamp":1640325071000},"page":"e2056-e2064","source":"Crossref","is-referenced-by-count":12,"title":["Value of Somatostatin Receptor PET\/CT in Patients With MEN1 at Various Stages of Their Disease"],"prefix":"10.1210","volume":"107","author":[{"given":"Cl\u00e9ment","family":"Mennetrey","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u00eblle","family":"Le Bras","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Nutrition, l\u2019institut du thorax, CHU Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Bando-Delaunay","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Department of Nuclear Medicine, Beaujon University Hospital (APHP.Nord), Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Al-Mansour","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospices Civils of Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magalie","family":"Haissaguerre","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Haut Leveque University Hospital, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Batisse-Lignier","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Ouvrard","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging \u2013 Institut de Canc\u00e9rologie de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS\/University of Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, CHU de Nantes, H\u00f4tel-Dieu, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospices Civils of Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"de Mestier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Department of Gastroenterology-Pancreatology, Beaujon University Hospital (APHP. Nord), Clichy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghoufrane","family":"Tlili","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Haut Leveque University Hospital, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Giraud","sequence":"additional","affiliation":[{"name":"Genetics Department, Hospices Civils de LYON (HCL), University Hospital, East Pathology Center, LYON"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Odile","family":"North","sequence":"additional","affiliation":[{"name":"Department of Genetic & Molecular Biology, H\u00f4pital Cochin, Assistance Publique-H\u00f4pitaux de Paris, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Fran\u00e7oise","family":"Odou","sequence":"additional","affiliation":[{"name":"Laboratory of biochemistry and molecular biology, Lille university hospital, Inserm U1286, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University hospitals of Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Conception Hospital, Aix-Marseille University, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-9476","authenticated-orcid":false,"given":"Anderson","family":"Loundou","sequence":"additional","affiliation":[{"name":"Department of Public health, Aix-Marseille University, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Romanet","sequence":"additional","affiliation":[{"name":"Aix Marseille Univ, APHM, INSERM, MMG, Laboratory of Molecular Biology Hospital La Conception, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Imperiale","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Molecular Imaging \u2013 Institut de Canc\u00e9rologie de Strasbourg Europe (ICANS), IPHC, UMR 7178, CNRS\/University of Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-7600","authenticated-orcid":false,"given":"David","family":"Ta\u00efeb","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"issue":"4","key":"2022041907515226600_CIT0001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41574-021-00468-3","article-title":"Clinical aspects of multiple endocrine neoplasia type 1","volume":"17","author":"Al-Salameh","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"6","key":"2022041907515226600_CIT0002","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/SLA.0000000000003162","article-title":"Metastatic potential and survival of duodenal and pancreatic tumors in multiple endocrine neoplasia type 1: a GTE and AFCE Cohort Study (Groupe d\u2019\u00e9tude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne)","volume":"272","author":"Vinault","year":"2020","journal-title":"Ann Surg."},{"issue":"3","key":"2022041907515226600_CIT0003","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/MD.0b013e3182954af1","article-title":"Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1\/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors","volume":"92","author":"Ito","year":"2013","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"2022041907515226600_CIT0004","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1097\/SLA.0000000000001211","article-title":"Better survival but changing causes of death in patients with multiple endocrine neoplasia type 1","volume":"261","author":"Norton","year":"2015","journal-title":"Ann Surg."},{"issue":"2","key":"2022041907515226600_CIT0005","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00268-009-0290-1","article-title":"Risk factors and causes of death in MEN1 disease. A GTE (Groupe d\u2019Etude des Tumeurs Endocrines) cohort study among 758 patients","volume":"34","author":"Goudet","year":"2010","journal-title":"World J Surg."},{"issue":"3","key":"2022041907515226600_CIT0006","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/jc.2002-021314","article-title":"Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1","volume":"88","author":"Gibril","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022041907515226600_CIT0007","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1210\/jc.2014-3659","article-title":"MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019\u00e9tude des Tumeurs Endocrines","volume":"100","author":"Goudet","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022041907515226600_CIT0008","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/cen.13119","article-title":"Utility of chromogranin A, pancreatic polypeptide, glucagon and gastrin in the diagnosis and follow-up of pancreatic neuroendocrine tumours in multiple endocrine neoplasia type 1 patients","volume":"85","author":"Qiu","year":"2016","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"10","key":"2022041907515226600_CIT0009","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1210\/jc.2013-1800","article-title":"Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients","volume":"98","author":"de Laat","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"2022041907515226600_CIT0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fendo.2019.00339","article-title":"Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis","volume":"10","author":"Kamilaris","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2022041907515226600_CIT0011","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.dld.2020.02.011","article-title":"Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)","volume":"52","author":"de Mestier","year":"2020","journal-title":"Dig Liver Dis."},{"issue":"9","key":"2022041907515226600_CIT0012","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s12149-012-0634-z","article-title":"Impact of Ga-68 DOTATOC PET\/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia","volume":"26","author":"Froeling","year":"2012","journal-title":"Ann Nucl Med."},{"issue":"2","key":"2022041907515226600_CIT0013","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jamcollsurg.2015.04.005","article-title":"Results of (68)Gallium-DOTATATE PET\/CT Scanning in patients with multiple endocrine neoplasia type 1","volume":"221","author":"Sadowski","year":"2015","journal-title":"J Am Coll Surg."},{"issue":"3","key":"2022041907515226600_CIT0014","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12020-015-0702-y","article-title":"Role of (68)Ga-DOTATATE PET\/CT in patients with multiple endocrine neoplasia type 1 (MEN1)","volume":"52","author":"Lastoria","year":"2016","journal-title":"Endocrine."},{"issue":"7","key":"2022041907515226600_CIT0015","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-016-3319-3","article-title":"Evaluation of (68)Ga-DOTA-TOC PET\/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1","volume":"43","author":"Morgat","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2022041907515226600_CIT0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/wjnm.WJNM_24_19","article-title":"Comparison of 68Ga-DOTA-NaI3-Octreotide\/tyr3-octreotate positron emission tomography\/computed tomography and contrast-enhanced computed tomography in localization of tumors in multiple endocrine neoplasia 1 syndrome","volume":"19","author":"Patil","year":"2020","journal-title":"World J Nucl Med."},{"issue":"1","key":"2022041907515226600_CIT0017","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/cpf.12391","article-title":"Role of positron emission tomography imaging in multiple endocrine neoplasia syndromes","volume":"38","author":"July","year":"2018","journal-title":"Clin Physiol Funct Imaging."},{"key":"2022041907515226600_CIT0018","doi-asserted-by":"crossref","first-page":"654975","DOI":"10.3389\/fendo.2021.654975","article-title":"The impact of 68Gallium DOTA PET\/CT in managing patients with sporadic and familial pancreatic neuroendocrine tumours","volume":"12","author":"Cuthbertson","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"2022041907515226600_CIT0019","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1159\/000511791","article-title":"Multiple endocrine neoplasia type 1 and the pancreas: diagnosis and treatment of functioning and non-functioning pancreatic and duodenal neuroendocrine neoplasia within the MEN1 syndrome \u2013 an international consensus statement","volume":"111","author":"Niederle","year":"2021","journal-title":"Neuroendocrinology."},{"issue":"9","key":"2022041907515226600_CIT0020","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022041907515226600_CIT0021","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1210\/jc.2018-01170","article-title":"UMD-MEN1 database: an overview of the 370 MEN1 variants present in 1676 patients from the French population","volume":"104","author":"Romanet","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022041907515226600_CIT0022","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med."},{"issue":"6","key":"2022041907515226600_CIT0023","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/humu.23746","article-title":"Proposition of adjustments to the ACMG-AMP framework for the interpretation of MEN1 missense variants","volume":"40","author":"Romanet","year":"2019","journal-title":"Hum Mutat."},{"author":"Mennetrey","key":"2022041907515226600_CIT0024"},{"issue":"1","key":"2022041907515226600_CIT0025","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2217\/ije.15.29","article-title":"Imaging in multiple endocrine neoplasia type 1: recent studies show enhanced sensitivities but increased controversies","volume":"3","author":"Ito","year":"2016","journal-title":"Int J Endocr Oncol."},{"issue":"5","key":"2022041907515226600_CIT0026","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/01.pas.0000194044.01104.25","article-title":"Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome","volume":"30","author":"Anlauf","year":"2006","journal-title":"Am J Surg Pathol."},{"key":"2022041907515226600_CIT0027","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/s00428-007-0450-3","article-title":"Hereditary neuroendocrine tumors of the gastroenteropancreatic system","volume":"451","author":"Anlauf","year":"2007","journal-title":"Virchows Arch."},{"issue":"5","key":"2022041907515226600_CIT0028","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.semnuclmed.2021.03.001","article-title":"Variants and pitfalls of PET\/CT in neuroendocrine tumors","volume":"51","author":"Imperiale","year":"2021","journal-title":"Semin Nucl Med."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab891\/42092444\/dgab891.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/e2056\/43386366\/dgab891.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/107\/5\/e2056\/43386366\/dgab891.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T07:53:49Z","timestamp":1650354829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/107\/5\/e2056\/6481711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,12,23]]},"published-print":{"date-parts":[[2022,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab891","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"type":"print","value":"0021-972X"},{"type":"electronic","value":"1945-7197"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2021,12,23]]}}}